A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus
Status:
Not yet recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream in
participants With Lichen Sclerosus. This is randomized, double-blind, vehicle-controlled
(DBVC) study with a DBVC period of 12 weeks followed by an open label period (OLE) period of
12 weeks.